trial

Effects of Delta-9-THC and Iomazenil in Healthy Humans

NCTId NCT00982982
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Early Phase 1 · Completed
Enrollment 17 (actual)
Sponsored by Yale University
Primary completion 2013-02-22
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Early Phase 1
Status
Completed
Enrollment
17 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2009-02-11
Primary completion
2013-02-22
Eligibility
MALE · 18 Years · 55 Years

Interventions & indications

Drugs
THC and Iomazenil

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Deepak C D'Souza, M.D.Principal Investigator

Sites

1 total
West Haven, United States

Facts & assertions

4 sourced
Enrollment
17
Phase
EARLY_PHASE1
Primary Completion Date
2013-02-22
Status
COMPLETED
relationships
The graph out of here
drug
THC and Iomazenil
drug
lead_sponsor
Yale University
company
indication
Psychotic Disorders
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Psychotic Disorders
indication
investigator
Deepak C D'Souza, M.D.
person